Lambert, J., Paul, C., Gottlieb, A. and Poulin, Y. (2022) “Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials”, SKIN The Journal of Cutaneous Medicine, 6(6), p. s45. doi: 10.25251/skin.6.supp.45.